Exergaming improves quality of life in heart failure patients
Exergaming or playing video games that involve physical exertion e.g. playing virtual tennis, improves quality of life in patients with heart failure, suggest the HF-Wii study presented May 27, 2018 at Heart Failure 2018 and the World Congress on Acute Heart Failure. Patients in the exergame group could.... read more
Socioeconomic factors influence hospitalization in sarcoidosis patients
Analysis of data from the FSR-Sarcoidosis Advanced Registry for Cures (FSR-SARC) presented May 22, 2018 at the recent American Thoracic Society (ATS) 2018 Conference in San Diego has shown that female gender, higher self-reported income, younger age and shorter disease duration were independent predictors of lower hospitalization rates in patients with sarcoidosis.
.... read more
Study shows encouraging results with cabozantinib for malignant pheochromocytoma
Preliminary data presented at the American Association of Clinical Endocrinologists (AACE) 2018 Annual Scientific & Clinical Congress in Boston show encouraging results with cabozantinib as treatment for patients with malignant unresectable pheochromocytomas and paragangliomas...... read more
Visual outcomes improve with pulse IV steroids in VKD disease
Aggressive treatment beginning with pulsed intravenous corticosteroids resulted in excellent visual outcomes and low rates of recurrence in patients with new-onset acute Vogt-Koyanagi-Harada (VKH) disease, according to a study reported online May 8, 2018 in the British Journal of Ophthalmology.
..... read more
Antibiotics prescribed for hospitalized patients with asthma exacerbation are often unnecessary
Antibiotics are often prescribed for hospitalized patients with acute exacerbation of asthma without lung infection, where they are unnecessary and moreover associated with increased length of stay and risk for antibiotic-related diarrhea, with no apparent benefit. These findings were presented May 22, 2018 at the American Thoracic Society International Conference in San Diego...... read more
US FDA approves Xience Sierra, the latest in DES
The US Food and Drug Administration (FDA) has approved the Xience Sierra (Abbott) everolimus-eluting coronary stent, the newest generation of Xience stent for complex cases, including patients with multiple or totally blocked vessels. The highlighting features of Xience Sierra include a thinner profile, increased flexibility, increased lengths and smaller diameters than previous stents..... read more